ADAG:NASDAQ, Adagene Inc.
ADAG stock overview
Adagene Inc. (ADAG:NASDAQ) closed at $2.29 on November 2, 2026,
down 8.76% on the day.
The stock trades 52.8% below its 52-week high of $4.85
and 76.2% above its 52-week low of $1.30.
Over the past year, it gained 27.9%.
Adagene Inc. is part of the Health Care sector.
Key figures
- Price
- $2.29
- Day change
- -8.76%
- Volume
- 181,778
- Average volume
- 281,634
- Market cap
- 153M+
- 52-week range
- $1.30 – $4.85
- 50-day average
- $3.02
- 200-day average
- $3.43
Price action over the past year
In 252 trading sessions since October 31, 2025, ADAG closed higher on 119 days (47%).
Its best day was January 23, 2026 (+22.66%) and its worst was October 16, 2026 (-14.17%).
The stock moved 10% or more in a single session 24 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
ADAG news
-
Oct 31, 2026:
What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?
-
Oct 28, 2026:
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
-
Oct 27, 2026:
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
-
Oct 25, 2026:
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
-
Oct 16, 2026:
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
-
Oct 14, 2026:
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
-
Sep 22, 2026:
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
-
Sep 10, 2026:
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody Technology
About Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Similar stocks
Find more stocks like ADAG with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.